Vaccine Development Global Program

Developing new, affordable vaccines for the people who need them most

Vaccines are one of the most effective, affordable, and beneficial tools in public health. Because market forces alone are not always strong enough to drive the development of vaccines most urgently needed in lower-income countries, PATH’s Vaccine Development Global Program is stepping in to fill the gap. Find out more »

Protecting mom and baby from infectious diseases

PATH fact sheet. Protecting mother and baby from infectious diseases. April 2016.Mothers and children deserve the chance to reach their full potential, no matter where they live. A promising way to prevent disease in these populations is maternal immunization—an approach of vaccinating during pregnancy to enhance immunity for both mother and baby. Learn how PATH is advancing maternal immunization strategies against respiratory syncytial virus, influenza, and pertussis (whooping cough.) Read the fact sheet (PDF 299.24 KB)»


fact sheet: Read the latest on our pneumococcal vaccine work (PDF 434 KB)  »

blog: #ProtectingKids series highlights immunization stories from the field »

resource: WHO launches new vaccine pipeline tracker »

blog: When a newborn’s cold is more than a cold, it may be RSV and time for help »

event: Join us at the Vaccines Against Shigella and ETEC (VASE) conference! »

Sign up for our e-newsletter

Our e-newsletter, Vaccines for the Future, provides quarterly updates on our efforts to develop innovative, safe, effective, and affordable vaccines. It includes updates on our progress, partnerships, and specific activities. Sign up now »

Visit the Vaccine Resource Library

PATH’s Vaccine Resource Library (VRL) seeks to gather the world’s best immunization resources in a single, easy-to-use website. The VRL offers high-quality, scientifically accurate documents and links on specific diseases and topics in immunization. Learn more »

Banner photos, clockwise from left: PATH/Gabe Bienczycki; PATH/Chutima Suraratdecha; PATH.

Comments are closed.